CERES BRAIN Therapeutics Information

CERES BRAIN Therapeutics is dedicated to treat cerebral diseases with a first focus on rescuing suffering neurons with creatine through an innovative "creatine-to-brain" concept. The first indication is the Creatine Transporter Deficiency syndrome, a disabling condition with no treatment affecting children. The lead compound CBT101 demonstrated efficacy in a two KO mice models as well as a large cerebral and neuronal distribution in primate. The CMC reached noticeable milestones both on the API with a scale-up of >5 kg and the formulation with a scale-up batch of 60 kg. Other mitochondriopathies are in the Ceres's pipeline. CERES BRAIN Therapeutics is currently raising founding to move towards the FiM planned for Q4/2023.